Article
Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
Cancer science - 1 Jan 2020
Sugimori Makoto, Sugimori Kazuya, Tsuchiya Hiromi, Suzuki Yoshimasa, Tsuyuki Sho, Kaneta Yoshihiro, Hirotani Akane, Sanga Katsuyuki, Tozuka Yuichiro, Komiyama Satoshi, Sato Takeshi, Tezuka Shun, Goda Yoshihiro, Irie Kuniyasu, Miwa Haruo, Miura Yuuki, Ishii Tomohiro, Kaneko Takashi, Nagahama Masatsugu, Shibata Wataru, Nozaki Akito, Maeda Shin
Abstract excerpt
According to cancer genome sequences, more than 90% of cases of pancreatic ductal adenocarcinoma (PDAC) harbor active KRAS mutations. Digital PCR (dPCR) enables accurate detection and quantification of rare mutations. We assessed the dynamics of circulating tumor DNA (ct-DNA) in patients with advanced PDAC undergoing chemotherapy using dPCR. KRAS G12/13 mutation was assayed by dPCR in 47 paired tissue- and ct-DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.